1-3 of 3
Sara Broering
Close
Sort by
Journal Articles

Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target C max Results in Improved Clinical Activity.

Thomas S. Lin, MD, PhD, Mitch Phelps, PhD, James T. Dalton, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Dimitrios Colevas, MD, John C. Byrd, MD, Michael R. Grever, MD
Journal: Blood
Blood (2006) 108 (11): 2845.
https://doi.org/10.1182/blood.V108.11.2845.2845
Published: 2006
Journal Articles

Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.

Thomas S. Lin, MD, PhD, Nyla A. Heerema, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Mollie E. Moran, CNP, Michelle B. McEldowney, CNP, Sara Broering, Gerard Lozanski, MD, Dimitrios Colevas, MD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 302.
https://doi.org/10.1182/blood.V108.11.302.302
Published: 2006
Journal Articles

Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.

Mollie E. Moran, MSN, Beth Fischer, MSN, Sara Broering, BS, Kristie A. Blum, MD, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Michael R. Grever, MD, Michelle Brooker-McEldowney, MSN
Journal: Blood
Blood (2005) 106 (11): 2124.
https://doi.org/10.1182/blood.V106.11.2124.2124
Published: 2005